Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
FG4-H5253 | Human | Human FGF R4 / CD334 Protein, Fc Tag (MALS & SPR verified) |
|
||
FG4-M52Ha | Mouse | Mouse FGF R4 / CD334 Protein, His Tag |
|
||
FG4-H5228 | Human | Human FGF R4 / CD334 Protein, His Tag |
|
Human FGF R4, Fc Tag (Cat. No. FG4-H5253) immobilized on CM5 Chip can bind Human FGF-4 Protein, His Tag (Cat. No. FG4-H51H3) with an affinity constant of 1.48 μM as determined in a SPR assay (Biacore 8K) (QC tested).
The purity of Human FGF R4, Fc Tag (Cat. No. FG4-H5253) is more than 90% and the molecular weight of this protein is around 145-175 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details |
Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Erdafitinib | G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV | Approved | Astex Pharmaceuticals Inc | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma | Details |
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details |
Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Erdafitinib | G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV | Approved | Astex Pharmaceuticals Inc | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms | Details |
Fisogatinib | BLU-554; CS-3008 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Hepatocellular | Details |
EVER-4010001 | EVER-4010001 | Phase 2 Clinical | EverNov Medicines (Zhuhai Hengqin) Co Ltd | Solid tumours | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
Roblitinib | FGF-401; NVP-FGF401 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
Irpagratinib | ABSK-011 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular | Details |
BPI-43487 | BPI-43487 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular | Details |
HS-236 | HS-236 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours | Details |
HS-10340 | HS-10340 | Phase 1 Clinical | Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours | Details |
ICP-105 | ICP-105 | Phase 1 Clinical | Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd | Liver Neoplasms; Solid tumours | Details |
ZSP-1241 | ZSP-1241 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
H3B-6527 | H3B-6527 | Phase 1 Clinical | H3 Biomedicine Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
SYHX-2005 | SYHX-2005; SYHX2005 | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Solid tumours | Details |
JAB-6343 | Phase 1 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details | |
SY-4798 | Phase 1 Clinical | Shouyao Holding (Beijing) Co Ltd | Solid tumours | Details | |
ABSK-012 | ABSK-012; ABSK012 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms | Details |
Fisogatinib | BLU-554; CS-3008 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Hepatocellular | Details |
EVER-4010001 | EVER-4010001 | Phase 2 Clinical | EverNov Medicines (Zhuhai Hengqin) Co Ltd | Solid tumours | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
Roblitinib | FGF-401; NVP-FGF401 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
Irpagratinib | ABSK-011 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular | Details |
BPI-43487 | BPI-43487 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular | Details |
HS-236 | HS-236 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours | Details |
HS-10340 | HS-10340 | Phase 1 Clinical | Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours | Details |
ICP-105 | ICP-105 | Phase 1 Clinical | Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd | Liver Neoplasms; Solid tumours | Details |
ZSP-1241 | ZSP-1241 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
H3B-6527 | H3B-6527 | Phase 1 Clinical | H3 Biomedicine Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
SYHX-2005 | SYHX-2005; SYHX2005 | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Solid tumours | Details |
JAB-6343 | Phase 1 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details | |
SY-4798 | Phase 1 Clinical | Shouyao Holding (Beijing) Co Ltd | Solid tumours | Details | |
ABSK-012 | ABSK-012; ABSK012 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.